Filing Details

Accession Number:
0001035267-23-000097
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-04-24 17:53:25
Reporting Period:
2023-04-21
Accepted Time:
2023-04-24 17:53:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1035267 Intuitive Surgical Inc ISRG Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) 770416458
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1277620 H Craig Barratt 1020 Kifer Road
Sunnyvale CA 94086
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-04-21 2,000 $41.26 2,000 No 4 M Direct
Common Stock Disposition 2023-04-21 2,000 $297.92 0 No 4 S Direct
Common Stock Acquisiton 2023-04-21 2,000 $41.26 2,000 No 4 M Direct
Common Stock Disposition 2023-04-21 2,000 $297.93 0 No 4 S Direct
Common Stock Acquisiton 2023-04-21 2,000 $41.26 2,000 No 4 M Direct
Common Stock Disposition 2023-04-21 2,000 $297.92 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2023-04-21 2,000 $0.00 2,000 $41.26
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2023-04-21 2,000 $0.00 2,000 $41.26
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2023-04-21 2,000 $0.00 2,000 $41.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,567 2024-04-24 No 4 M Direct
5,567 2024-04-24 No 4 M Direct
3,567 2024-04-24 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 24,696 Indirect by Trust
Footnotes
  1. These shares were sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on March 1, 2024.
  2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $296.42 to $299.21 as follows: 384 shares at $296.42 - $297.12; 1,216 shares at $297.57 -$298.50; 400 shares at $298.58 - $299.21. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $296.56 to $299.20 as follows: 404 shares sold at $296.56 - 297.56; 1,201 shares sold at $297.6 - $298.59; and 395 shares sold at $298.61 - $299.20. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $296.42 to $299.23 as follows: 366 shares sold at $296.42 - 297.14; 1,254 shares sold at $297.52 - $298.46; 380 shares sold at $298.63 - $299.23. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.